Salix Coronary Plaque vs Tempus ECG-AF

Loosely related. A direct comparison may be less useful — each tool solves a different problem. Comparability 40/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Salix Coronary Plaque

by Artrya

Tempus ECG-AF

by Tempus AI, Inc.

AI Verdict

These tools are not directly comparable as they address different aspects of cardiac health using distinct diagnostic modalities. Salix Coronary Plaque analyzes CCTA scans to assess coronary artery disease by quantifying plaque and stenosis, while Tempus ECG-AF analyzes 12-lead ECGs to predict the risk of atrial fibrillation in older patients. Therefore, the choice between them depends entirely on the specific clinical question and the type of cardiac assessment required.

Choose Salix Coronary Plaque if…

Choose Salix Coronary Plaque if your clinical workflow requires rapid, AI-driven analysis of CCTA scans for comprehensive coronary artery disease assessment. This tool is ideal for quantifying plaque burden, identifying high-risk plaque features, and assessing stenosis in near real-time, directly supporting point-of-care diagnostic decisions. It streamlines the evaluation of patients undergoing CCTA for suspected or known CAD.

View Salix Coronary Plaque →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if you need to proactively identify older patients (65+) at elevated risk of developing new-onset atrial fibrillation within the next year, utilizing standard 12-lead ECGs. This AI-based solution is best suited for screening asymptomatic or at-risk elderly populations without pre-existing AF, enabling earlier intervention and targeted follow-up to potentially prevent or manage future AF events.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Salix Coronary Plaque	Tempus ECG-AF
Pricing	Subscription model	Contact vendor
Deployment	Cloud-based (Amazon Web Services), web-based software application	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available	Yes AI-estimated	Yes AI-estimated
FDA Status	Yes AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Salix Coronary Plaque

Artrya Salix Coronary Plaque is a web-based software with an intuitive interface that requires minimal user training and no additional hardware or software installations, making it easy to deploy and integrate into existing workflows. It also provides near real-time results within minutes, which significantly improves efficiency for clinicians. Tempus ECG-AF is a software solution integrated into healthcare facility systems, but specific details on its user interface, ease of deployment, or training requirements are not as readily available.

Clinical Value

Salix Coronary Plaque

Artrya Salix Coronary Plaque offers a comprehensive assessment of coronary artery disease by detecting and quantifying various high-risk plaque features and stenosis from CCTA scans, which are often missed by traditional methods. This provides a full risk profile and supports personalized treatment options. Tempus ECG-AF identifies patients at increased risk of developing atrial fibrillation/flutter within 12 months, which is valuable for early detection, but its scope is narrower, focusing on a single condition and patient demographic.

Pricing & Value

Salix Coronary Plaque

Artrya Salix Coronary Plaque has a clear reimbursement rate of US$950 per automated plaque assessment, which can generate significant additional revenue for healthcare providers and turn cardiac diagnostics into a revenue center. While Tempus ECG-AF also has CMS reimbursement available (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90), the per-scan revenue generation appears to be substantially lower.

Enterprise Readiness

Salix Coronary Plaque

Artrya Salix Coronary Plaque is a cloud-based, web-based software that integrates seamlessly into existing clinical workflows and CCTA scanners, requiring no capital equipment investment. It has established strategic partnerships with multiple US hospital systems for commercial deployment and is actively expanding its market presence. Tempus ECG-AF is integrated into healthcare facility systems, but the extent of its enterprise-level deployment and integration capabilities is less detailed.

Innovation

Salix Coronary Plaque

Artrya Salix Coronary Plaque utilizes AI to provide near real-time, human-free analysis of CCTA scans, identifying high-risk plaque features that are often overlooked by traditional methods. This shifts the treatment paradigm from reactive to preventative. Tempus ECG-AF is also innovative in its use of AI for ECG analysis to predict AF risk, but Artrya's solution appears to address a broader and more complex diagnostic challenge in cardiac imaging.

Support & Docs

Tie

Both products are FDA-cleared and provide documentation regarding their intended use and limitations. Artrya Salix Coronary Plaque mentions automated report generation and integration with existing systems. Tempus ECG-AF provides an 'Instructions for Use' document and emphasizes that results should be interpreted in conjunction with other diagnostic information. However, neither product explicitly details the breadth or depth of their customer support, training programs, or publicly available documentation beyond basic product information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Salix Coronary Plaque	Tempus ECG-AF
Name	Salix Coronary Plaque	Tempus ECG-AF
Company	Artrya	Tempus AI, Inc.
Description	FDA-cleared, AI-driven, web-based software that provides near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans, aiding in the rapid and accurate diagnosis of coronary artery disease.	FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up.
Key Features	AI-enabled CCTA analysis; Near real-time, point-of-care assessment; Detection and quantification of coronary plaque (atherosclerosis); Identification of high-risk plaque features (e.g., low-attenuation plaque, spotty calcification, positive remodeling, napkin-ring sign); Stenosis assessment; Quantification of calcifications (calcium scoring); Integrated workflow management; Automated report generation (editable)	AI-based algorithm for 12-lead ECG analysis; Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months; Intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery; Results interpreted in conjunction with other diagnostic information and clinical history; Compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems; Trained on over 1.5 million ECGs from over 500,000 patients
Specialties	Cardiology, Radiology	Cardiology, Geriatrics, Internal Medicine
Headquarters	Perth, Western Australia, Australia	Not specified

Videos

Demos, reviews, and walkthroughs featuring Salix Coronary Plaque and Tempus ECG-AF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications and target conditions for each AI tool?

Artrya Salix Coronary Plaque is designed for near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans, aiding in the rapid and accurate diagnosis of coronary artery disease. Tempus ECG-AF analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up.

What specific patient populations are each of these AI tools intended for?

Artrya Salix Coronary Plaque is intended for patients undergoing CCTA scans for coronary artery disease assessment. Tempus ECG-AF is for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, who are undergoing a 12-lead ECG.

What type of diagnostic input data does each AI tool require for analysis?

Artrya Salix Coronary Plaque processes CCTA scans to provide its assessment. Tempus ECG-AF analyzes 12-lead ECG recordings, specifically compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems.

How do the reimbursement mechanisms and rates compare for these two AI solutions?

Artrya Salix Coronary Plaque operates on a per-scan assessment model with a US CPT reimbursement rate of US$950 per assessment. Tempus ECG-AF has CMS reimbursement available via CPT 0764T and CPT 0765T to APC 5734, with a Medicare rate of $128.90 effective January 1, 2025.

What specific clinical insights or outputs do these tools provide to aid in patient management?

Artrya Salix Coronary Plaque provides detection and quantification of coronary plaque, identification of high-risk plaque features, stenosis assessment, and quantification of calcifications. Tempus ECG-AF detects signs associated with new onset Atrial Fibrillation (AF) within 12 months, with results interpreted in conjunction with other diagnostic information and clinical history.